liraglutide/insulin degludec (IDegLira)
Classes: Antidiabetics, Insulins; Antidiabetics, Long-Acting Insulins; Antidiabetics, Glucagon-like Peptide-1 Agonists
Dosing and uses of IDegLira (liraglutide/insulin degludec)
Type 2 Diabetes Mellitus
Pending FDA approval for treatment of adults with type 2 diabetes mellitus
Pediatric dosage forms and strengths
Safety and efficacy not established
Pharmacology of IDegLira (liraglutide/insulin degludec)
Mechanism of action
Insulin degludec: Long-acting basal insulin; lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production; insulin inhibits lipolysis and proteolysis and enhances protein synthesis; targets include skeletal muscle, liver, and adipose tissue
Liraglutide: Incretin mimetic; analogue of human glucagonlike peptide-1 (GLP-1); acts as GLP-1 receptor agonist to increase insulin secretion in the presence of elevated blood glucose; delays gastric emptying to decrease postprandial glucose; also decreases glucagon secretion
